Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Patients with acute myeloid leukemia (AML) who have previously undergone hypomethylating agent (HMA) therapy and failed it face a poor prognosis.
• Identifying effective treatment strategies for this patient subgroup is crucial.

Purpose of the Study:

• To investigate whether high-intensity induction chemotherapy can improve outcomes for patients with AML or other high-grade myeloid neoplasms who have prior HMA therapy.
• To compare overall survival (OS) and treatment failure rates between patients with and without prior HMA therapy.

Main Methods:

• Retrospective analysis of 270 patients with AML or other high-grade myeloid neoplasms.
• Comparison of outcomes (OS, treatment failure) in patients with prior HMA therapy versus a reference group without prior HMA therapy.
• Evaluation of the impact of high-intensity induction chemotherapy in patients with prior HMA therapy.

Main Results:

• Prior HMA therapy was significantly associated with lower overall survival (median 7.2 vs 13.1 months) compared to patients without prior HMA therapy.
• In patients with prior HMA therapy, high-intensity induction showed a non-significant trend toward longer OS (median 8.2 vs 4.8 months).
• High-intensity induction was associated with decreased treatment failure rates (39% vs 64%) in patients with prior HMA therapy.

Conclusions:

• Patients with AML and prior HMA failure demonstrate poor outcomes.
• High-intensity induction chemotherapy may offer a potential benefit in this patient population, warranting further investigation.
• Future studies should prospectively evaluate high-intensity induction chemotherapy in HMA-refractory AML.